Caremark IVIG denied: how to appeal

Quick answer

If CVS Caremark denied your IVIG and immunoglobulin, you can appeal, and the plan must give you its file and the criteria it used. Filing windows by plan type: at least 180 days (employer self-funded plans); at least 180 days (insured and Marketplace plans); 65 days from the notice (Part D); 60 days from the notice (Medicaid managed care). The date printed on your denial notice controls; it can only be later than these floors, never earlier.

Why CVS Caremark denies IVIG and immunoglobulin

CVS Caremark is one of the three largest pharmacy benefit managers in the U.S., administering drug coverage for commercial, Medicare Part D, and Medicaid plans. Caremark denials are issued at the pharmacy benefit layer, separate from the medical benefit, and have their own appeal track.

For IVIG and immunoglobulin specifically: Intravenous and subcutaneous immunoglobulin (IVIG, SCIG) is expensive, infused repeatedly, and reviewed against a short list of accepted diagnoses. Denials say 'not medically necessary' or 'experimental' for the specific condition, or move the drug to a different benefit or site of care.

The law that controls this appeal

Plans compare the diagnosis to their immunoglobulin policy, which typically lists FDA-labeled indications (primary immunodeficiency, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, Kawasaki disease, and others) and selected off-label uses supported by published evidence. Medicare Part B covers immunoglobulin for primary immunodeficiency at home under 42 CFR 410.10 and the home IVIG benefit; other indications follow local coverage determinations in the Medicare Coverage Database. Plan criteria must be disclosed on request (29 CFR 2560.503-1(m)(8); 45 CFR 147.136).

At a glance

CVS Caremark appeals: the rule, the deadline and the next level, by plan type

CVS Caremark adjudicates the pharmacy benefit for a plan sponsor, so the sponsor's rules govern the appeal: an employer plan (ERISA), an insured or Marketplace plan, Medicare Part D or Medicaid. The denial letter names the plan whose rules apply.

Plan type	Rule that governs	File your appeal within	The plan must answer	If the plan says no again
Employer self-funded plan (ERISA) Most large employers. The employer pays the claims and hires the carrier to administer them; the Summary Plan Description says self-funded or self-insured.	ERISA § 503 (29 U.S.C. § 1133) and the claims-procedure rule, 29 CFR 2560.503-1. Federal external review under 45 CFR 147.136(d) for non-grandfathered plans.	At least 180 days from the adverse benefit determination (29 CFR 2560.503-1(h)(3)(i)).	Urgent care: 72 hours. Pre-service: 30 days. Post-service: 60 days (29 CFR 2560.503-1(i)(2)).	Federal external review by an accredited independent review organization, requested within 4 months of the final internal denial (45 CFR 147.136(d)); then a civil action under ERISA § 502(a). State insurance departments do not regulate self-funded plans; the U.S. Department of Labor does.
Fully insured employer, individual or Marketplace plan The carrier holds the risk and is licensed in your state. Small employers and almost all individual and HealthCare.gov plans.	45 CFR 147.136 (Public Health Service Act § 2719), which applies the 29 CFR 2560.503-1 procedures and adds state external review; state insurance law on top.	At least 180 days from the denial (45 CFR 147.136(b); 29 CFR 2560.503-1(h)(3)(i)).	Urgent care: 72 hours. Pre-service: 30 days. Post-service: 60 days. Prior-authorization decisions by Marketplace issuers from 2026: 72 hours expedited, 7 calendar days standard (CMS-0057-F).	External review through your state's process, or the federal process where the state has none, generally within 4 months of the final internal denial (45 CFR 147.136(c), (d)). The state insurance department and its Consumer Assistance Program take complaints.
Medicare Part D (drug plan or MA-PD) A stand-alone drug plan or the drug benefit inside a Medicare Advantage plan.	42 CFR Part 423, Subpart M; exceptions under 42 CFR 423.578.	65 calendar days from the date on the notice to request a redetermination (42 CFR 423.582, as amended effective 1 January 2025). Formulary, tiering and step-therapy exceptions need the prescriber's supporting statement (§ 423.578).	Redetermination: 7 calendar days standard, 72 hours expedited (42 CFR 423.590). Coverage determinations: 72 hours standard, 24 hours expedited, once the prescriber's statement is received (§§ 423.568, 423.572).	Independent Review Entity reconsideration on your request within 65 days of the redetermination notice (§ 423.600); then ALJ, Council and court.
Medicaid managed care plan A Medicaid plan run by the carrier under a state contract. The card says Medicaid, Medi-Cal, STAR, HealthChoice or your state's programme name.	42 CFR Part 438, Subpart F (plan appeals) and 42 CFR Part 431, Subpart E (state fair hearings).	60 calendar days from the date on the notice of adverse benefit determination to request the plan's appeal (42 CFR 438.402(c)(2)(ii)). State fair hearing: within 120 calendar days of the plan's appeal decision (§ 438.408(f)(2)).	Standard appeal: 30 calendar days. Expedited: 72 hours (42 CFR 438.408(b)).	A state fair hearing after the plan's single level of appeal (§ 438.402(b)); some states add an external medical review. Benefits continue during the appeal if you ask within 10 calendar days of the notice (§ 438.420).

Employer self-funded plan (ERISA)

What you can demand. The plan must give you the claim file, the internal rule or criterion it relied on, and the identity of the reviewer, free of charge, on request (29 CFR 2560.503-1(h)(2)(iii), (m)(8)).

How to open the appeal. Cite ERISA § 503 and 29 CFR 2560.503-1 in the opening paragraph: request the claim file and the specific criteria relied on, and note the 30-day (pre-service), 60-day (post-service) and 72-hour (urgent) decision clocks.

Fully insured employer, individual or Marketplace plan

What you can demand. The plan must give you the claim file, the criteria it applied and any new evidence or rationale before the final decision, free of charge (45 CFR 147.136(b)(2)(ii)(C); 29 CFR 2560.503-1(h)(2)(iii)).

How to open the appeal. Cite 45 CFR 147.136 and 29 CFR 2560.503-1: request the claim file and the criteria, note the decision clocks, and name the state external-review right.

Medicare Part D (drug plan or MA-PD)

What you can demand. The exception turns on the prescriber's statement that the formulary alternative would be less effective or would harm you (42 CFR 423.578(b)(5)).

How to open the appeal. Cite 42 CFR 423.578 and 423.582 and attach the prescriber's supporting statement written to the exception standard.

Medicaid managed care plan

What you can demand. Free copies of the case file, medical records and the criteria used, before and during the appeal (42 CFR 438.406(b)(5)). Children under 21 have EPSDT rights to medically necessary care (42 U.S.C. 1396d(r)(5)).

How to open the appeal. Cite 42 CFR 438.402 and 438.406(b)(5): request the case file and the criteria, ask for continued benefits within 10 days, and reserve the state fair hearing.

Primary sources for this table

Windows are federal floors or the rule as written; the denial notice controls. Reviewed 13 September 2026. General information, not legal advice; Apellica is not a law firm.

What CVS Caremark denies for IVIG and immunoglobulin

The IVIG and immunoglobulin services most often denied:

IVIG for CIDP, myasthenia gravis, dermatomyositis, or autoimmune encephalitis
Continuation after the initial authorization period when response is not documented
Dose or frequency above the policy's stated range
Site-of-care changes: hospital outpatient infusion moved to home or a standalone center
Subcutaneous immunoglobulin when the plan prefers intravenous

Why IVIG and immunoglobulin claims get denied

A typical CVS Caremark IVIG and immunoglobulin denial almost always cites one of these reasons. Each one maps to a specific rebuttal in the appeal:

Diagnosis not on the plan's list of covered indications
Required baseline labs (immunoglobulin levels, vaccine response, nerve conduction studies) not in the record
No documented failure of first-line therapy where the policy requires it
Response to prior IVIG cycles not documented in measurable terms
Plan classifies the use as experimental or investigational

The CVS Caremark appeal process

Appeal levels: Coverage determination / exception request, then plan-level redetermination, then external review (IRO for commercial; IRE / MAXIMUS for Medicare Part D).

Carrier timing: Standard exception requests: 72 hours commercial / 72 hours Part D. Expedited: 24 hours. Redetermination filing window: 65 days from the notice for Part D (42 CFR 423.582), at least 180 days for commercial.

IVIG timing: Ongoing infusions make most IVIG appeals urgent: request expedited review and expect a decision within 72 hours (29 CFR 2560.503-1(f)(2)(i); 42 CFR 422.584 for Medicare Advantage). Internal appeal filing window: at least 180 days for commercial and employer plans; 65 days for Medicare Advantage; 60 days for Part D redetermination (42 CFR 423.582). External review must be requested within 4 months of the final internal denial for ACA-covered plans.

What we know about CVS Caremark: Caremark and the medical-benefit carrier (e.g. Aetna) maintain separate appeal records. We file in the correct lane from the start so the clock does not run on the wrong track.

Common CVS Caremark denial patterns for IVIG and immunoglobulin

Formulary and tiering exception requests. Most Caremark denials are formulary or tiering issues: a drug is non-formulary, on a higher tier, or subject to step therapy. The standard appeal lane is a formulary or tiering exception with the prescriber's clinical justification.
Specialty drug prior authorization. High-cost specialty drugs (biologics, oncology, MS, RA) route through Caremark Specialty and require detailed clinical documentation. Manufacturer-supplied clinical dossiers and FDA label citations speed the exception process.
Part D coverage determination ladder. For Medicare Part D plans administered by Caremark, denials follow the federal Part D appeal ladder: coverage determination → redetermination → IRE (MAXIMUS) → ALJ → Council → federal court. Each level has its own short deadline.

How to win your CVS Caremark IVIG and immunoglobulin appeal

Strategy for IVIG and immunoglobulin: Request the plan's immunoglobulin policy and the reviewer's specialty. Have the treating specialist write to each criterion: diagnosis with supporting labs or electrodiagnostic studies, prior therapies and results, measurable response to IVIG, and dosing rationale. For off-label uses, attach the guideline or peer-reviewed evidence the specialist relies on and identify it accurately. If the denial is 'experimental', the external review process specifically covers that determination (45 CFR 147.136(d)).

Filed against CVS Caremark, that strategy rides on this procedural spine:

Procedural-rights anchor. Cite ERISA § 503 and 29 CFR 2560.503-1 in the opening paragraph: request the claim file and the specific criteria relied on, and note the 30-day (pre-service), 60-day (post-service) and 72-hour (urgent) decision clocks. If your CVS Caremark coverage is a different plan type (Fully insured employer, individual or Marketplace plan, Medicare Part D, Medicaid managed care plan), use that row of the table above instead; the rule and the deadline change with the plan, not the carrier.
Criteria-disclosure demand. CVS Caremark frequently denies on "not medically necessary" without disclosing the clinical criteria applied. Once disclosed, those criteria become the rebuttal map.
Controlling-standard citation. Plans compare the diagnosis to their immunoglobulin policy, which typically lists FDA-labeled indications (primary immunodeficiency, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, Kawasaki disease, and others) and selected off-label uses supported by published evidence. Medicare Part B covers immunoglobulin for primary immunodeficiency at home under 42 CFR 410.10 and the home IVIG benefit; other indications follow local coverage determinations in the Medicare Coverage Database. Plan criteria must be disclosed on request (29 CFR 2560.503-1(m)(8); 45 CFR 147.136).
Treating-provider attestation. A letter from the treating physician addressing each criterion in CVS Caremark's own policy language. This is the single strongest evidentiary element.
Requested action. A specific demand to reverse the IVIG and immunoglobulin denial and approve the service, not a general "please reconsider."

Documents you'll need for your CVS Caremark IVIG and immunoglobulin appeal

The denial letter naming the criterion or policy applied
Specialist's notes with diagnosis, labs, and electrodiagnostic or imaging results
Record of prior therapies and outcomes
Infusion records showing dose, frequency, and documented response
The plan's immunoglobulin policy (request it in writing)

What a IVIG and immunoglobulin appeal can recover

Typical recovery for IVIG and immunoglobulin cases runs Immunoglobulin is among the most expensive recurring therapies; a denied course commonly represents thousands of dollars per infusion in billed charges.. The exact figure depends on the specific service and your plan's contracted rates.

CVS Caremark IVIG and immunoglobulin appeals: frequently asked questions

CVS Caremark says IVIG is experimental for my condition. Can that be appealed?

Yes. 'Experimental or investigational' determinations are appealable internally and are expressly within the scope of external review. The strongest appeals identify the published guideline or evidence the specialist relies on and show it directly.

My infusions are scheduled this week. What do I do first?

Ask for an expedited appeal in writing and have the prescriber confirm that delay could seriously jeopardize health. Expedited decisions are due within 72 hours.

CVS Caremark approved IVIG before. Why is it denied now?

Continuation reviews look for measurable response. If the record only says 'doing well', the plan may treat that as no evidence. The specialist's note should record the objective measures the policy asks for.

Does CVS Caremark have to tell me which policy it used?

For employer and ACA plans, yes: the internal rule, guideline, or protocol relied on must be provided free on request. Ask for it by name in the appeal.

What Apellica does for CVS Caremark IVIG and immunoglobulin appeals

We file appeals against CVS Caremark specifically configured to its internal review process. Every IVIG and immunoglobulin appeal embeds the criteria-disclosure demand, the procedural-rights anchor, the controlling-standard citation above, treating-provider attestation language, and the peer-reviewed evidence relevant to the denied service.

Cost: $0 upfront. We work on contingency for CVS Caremark appeals, if the appeal succeeds, we collect a percentage of the recovered claim value. If it fails, you owe nothing.

Start your CVS Caremark IVIG and immunoglobulin appeal

Submit a 2-minute intake. A senior reviewer responds within one business day with the specific appeal strategy for your case.

Start free appeal review →

CVS Caremark denied your IVIG and immunoglobulin? Here is what to do next